HUTCHMED (China) (HCM) vs Disc Medicine (IRON)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Disc Medicine (IRON) has outperformed HUTCHMED (China) (HCM) over the past year, losing 13.5% versus a loss of 16.6%. Over five years, IRON leads with a -45.5% price change compared with -57.7% for HCM. HUTCHMED (China) is the larger company by market cap ($2.38 billion vs $2.33 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HCM | IRON |
|---|---|---|
| Share price | $13.67 | $60.77 |
| Market cap | $2.38B | $2.33B |
| 1-day change | -4.27% | -0.67% |
| YTD return | +2.55% | -23.47% |
| 1-year return | -16.60% | -13.53% |
| 5-year return | -57.68% | -45.55% |
| P/E ratio (TTM) | 136.70 | — |
| Forward P/E | 52.74 | — |
| EPS (TTM) | $0.10 | $-6.58 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $548.51M | — |
| Revenue growth (YoY) | -12.96% | — |
| Net income (latest FY) | $456.91M | — |
| Gross margin | 38.68% | — |
| Operating margin | -7.14% | — |
| Net margin | 83.30% | — |
| 52-week high | $16.33 | $99.50 |
| 52-week low | $9.77 | $40.00 |
| Distance from 52-week high | -16.29% | -38.92% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +61.01% | +69.77% |
| Average volume | 68.02K | 471.18K |
| Shares outstanding | 173.81M | 38.39M |
| Employees | 1,790 | 165 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About HUTCHMED (China)
HCM stock →HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,790 employees
About Disc Medicine
IRON stock →Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.
Health Care · Biotechnology: Pharmaceutical Preparations · 165 employees
HCM vs IRON FAQ
Which is bigger, HUTCHMED (China) or Disc Medicine?
HUTCHMED (China) (HCM) is larger, with a market capitalization of $2.38B compared with $2.33B for Disc Medicine (IRON).
Which stock has performed better over the past year, HCM or IRON?
IRON returned -13.53% over the past 12 months, compared with -16.60% for HCM (price return, excluding dividends). Past performance does not predict future results.
Are HUTCHMED (China) and Disc Medicine in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.